Late Onset Hepatitis and Prolonged Deterioration in Hepatic Function Associated with Nevirapine Therapy
- 1 May 2000
- journal article
- case report
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 11 (5) , 336-337
- https://doi.org/10.1177/095646240001100511
Abstract
The aetiology of hepatic dysfunction in patients with HIV infection is multifactorial. Re-activation of hepatitis C infection, drug toxicity, and opportunistic infections are all potential causes. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection. It is associated with a significant incidence of hepatotoxicity, usually occurring in the initial month of therapy. We report the case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy.Keywords
This publication has 5 references indexed in Scilit:
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 InfectionAnnals of Internal Medicine, 1996
- A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patientsAIDS, 1996
- High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1995